Attovia Therapeutics, Inc.
Support and Resistance Levels
Past performance
News About ATTO
All events for ATTO
All deals for ATTO
Financial Ratios
Financial Statements
ATTO vs Sector & Peers
About Attovia Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases. Website attovia.com
Headquarters San Carlos, CA, US